CPL207280

CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes[1][2].

Product Specifications

CAS Number

[2361497-72-3]

UNSPSC

12352005

Target

Free Fatty Acid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/cpl207280.html

Purity

98.72

Solubility

10 mM in DMSO

Smiles

OC(C[C@@H](C1=CC=C(C=C1)OC/C(C)=C(C)/C)C#CC)=O

Molecular Formula

C18H22O3

Molecular Weight

286.37

References & Citations

[1]Mach M, et al. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem. 2021;226:113810.|[2]Bazydlo-Guzenda K, et al. CPL207280-a novel GPR40/FFA1-specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals[J]. Molecular Pharmacology, 2021.